Main Menu

ASCO 2022: Cancer researchers unite for in-person meeting


World-leading cancer researchers will be gathering in Chicago from 3 to 7 June for the ASCO Annual Meeting – the first to take place in person since the Covid-19 pandemic. We look ahead at some of the ICR’s research highlights that will be presented at this year’s meeting.

Posted on 30 May, 2022 by Gege Li


Starting from Friday, researchers at The Institute of Cancer Research, London, will be part of a global throng of cancer scientists and clinicians attending and presenting at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

ASCO is perhaps the biggest event in oncology calendar, and this year’s conference is once again taking place in person after two years of virtual events, in a welcome indication that the world is getting back to normal after Covid-19. The conference will also be available online, with access to the full programme through livestream and on-demand sessions.

This year’s meeting theme is Advancing Equitable Cancer Care Through Innovation, focusing on the latest research advances and findings in cancer care that will help to improve patients’ lives and contribute to a more equitable future – be it through new innovations or smarter use of existing treatments.

We’ll be highlighting some of the studies being presented by researchers at the ICR and The Royal Marsden NHS Foundation Trust in the run up to ASCO 2022 – as well as releasing some exciting research from the conference. Please check our ASCO 2022 landing page for more information and updates.

Here are some of the ASCO abstracts featuring our researchers:

Poster sessions

  • Abstract 1019, on biomarkers in a PEARL trial cohort comparing palbociclib and fulvestrant versus capecitabine, presented by Dr Javier Pascual
  • Abstract 5041, on alkaline phosphatase decline and survival in metastatic castration-resistant prostate cancer patients treated with radium-223, presented by Professor Nick James
  • Abstract 8512, on pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer, presented by Professor Mary O’Brien
  • Abstract TPS2691, on a phase I trial of CBL-B inhibitor in patients with advanced solid tumour malignancies, presented by Dr Adam Sharp
  • Abstract TPS2704, on a phase I trial on an antibody-expressing virus as a single agent and combined with nivolumab in patient with advanced solid tumours, presented by Professor Kevin Harrington
  • Abstract TPS2705, on a phase I trial of RP3 virus as a single agent and combined with nivolumab in patients with solid tumours, presented by Professor Kevin Harrington
  • Abstract TPS9158, on a study into the safety and efficacy of inupadenant in combination with chemotherapy for metastatic non-small lung cancer, presented by Professor Mary O’Brien
  • Abstract TPS9159, on a phase III trial into pralsetinib for advanced or metastatic non-small cell lung cancer, presented by Professor Sanjay Popat

Sessions and panels

In addition, ICR researchers will be chairing or speaking at the following sessions and panels:

  • Education session on immunotherapy-radiotherapy combination for treating head and neck cancer, chaired by Professor Kevin Harrington
  • Education session on best approaches and updates for prostate cancer recurrence, with speaker Professor Chris Parker
  • Abstract 1009, on mutations and acquired resistance to fulvestrant in the plasmaMATCH study, presented by Dr Belinda Kingston
  • Symposium on biomarkers beyond histology in sarcoma clinical trials, with discussant Dr Paul Huang
  • Symposium on utility of genomics to guide treatments in patients with breast cancer, with discussant Professor Nick Turner
  • Panel on long-term survival data for immune checkpoint inhibitors, with speaker Dr Samra Turajlic

Join the conversation on social media with the hashtag #ASCO2022!

Read more news and stories from the ASCO Annual Meeting.

ASCO Annual Meeting


comments powered by Disqus